The activation of ERK1/2 and AKT pathways reflects the PI3K/PTEN signaling disruption that occurs in approximately 15%–20% of human gastric cancers and is associated with enhanced cell survival, proliferation, and therapeutic resistance (Zhao et al., 2019; Xu et al., 2018). Here, AKT1 is linked to gastric cancer.